Marker Therapeutics terminates Interim CFO; CEO assumes principal financial officer role

Marker Therapeutics, Inc.

On Nov 17, 2023, Marker terminated Danforth Advisors consulting agreement, effective Jan 16, 2024.
Eliot M. Lurier ceased as Interim CFO and Principal Financial and Accounting Officer immediately.
CEO Juan Vera appointed as Principal Financial and Accounting Officer effective Nov 17, 2023.
No replacement CFO has been announced; CEO will handle financial officer duties.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Eliot M. Lurier

Interim Chief Financial Officer and Principal Financial and Accounting Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2023-11-17
Successor: Juan Vera
Filed: November 20, 2023, 6:59 PM ET

On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer

Appointed

Juan Vera

Principal Financial and Accounting Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2023-11-17
Filed: November 20, 2023, 6:59 PM ET

Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eliot M. Lurier departed as Interim Chief Financial Officer and Principal Financial and Accounting Officer at Marker Therapeutics, Inc..

Action: ceased serving
Role: Interim Chief Financial Officer and Principal Financial and Accounting Officer

Exact text from the filing

On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Juan Vera was appointed as Principal Financial and Accounting Officer at Marker Therapeutics, Inc..

Action: appointed
Role: Principal Financial and Accounting Officer

Exact text from the filing

Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer.

View on SEC.gov

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-119946

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.